1.
Clinicopathological characteristics of RH and CCRT groups
| Characteristics | n (%) | |
| RH group
(n=360) |
CCRT group
(n=160) |
|
| RH, radical hysterectomy; CCRT, concurrent chemoradiotherapy; HPV, human papillomavirus; SCC-Ag, squamous cell carcinoma antigen; FIGO, International Federation of Gynecology and Obstetrics; G1/2/3, grade 1/2/3; LVSI, lymphovascular space invasion; LN, lymph node; LNSCT, lymph node status determined by computed tomography; NA, not applicable. | ||
| Age (year) | ||
| <35 | 69 (19.17) | 17 (10.63) |
| 35−50 | 224 (62.22) | 78 (48.75) |
| >50 | 67 (18.61) | 65 (40.63) |
| HPV viral load (RLU/CO) | ||
| Median | 356.10 | 294.29 |
| <100 | 130 (36.11) | 44 (27.50) |
| 100−1,000 | 173 (48.06) | 85 (53.12) |
| >1,000 | 57 (15.83) | 31 (19.38) |
| SCC-Ag (ng/mL) | ||
|
2.32±5.19 | 9.06±28.01 |
| <1.5 | 238 (66.11) | 51 (31.88) |
| 1.5−5.0 | 89 (24.72) | 52 (32.50) |
| 5.0−10.0 | 20 (5.56) | 28 (17.50) |
| >10.0 | 13 (3.61) | 29 (18.12) |
| FIGO stage | ||
| IB1 | 208 (57.77) | NA |
| IB2 | 114 (31.67) | NA |
| IIA | 38 (10.56) | NA |
| IIB | NA | 111 (69.38) |
| IIIA | NA | 4 (2.50) |
| IIIB | NA | 43 (26.87) |
| IVA | NA | 2 (1.25) |
| Tumor size (cm) | ||
| <2 | 68 (18.89) | 3 (1.88) |
| 2−4 | 151 (41.94) | 17 (10.62) |
| >4 | 141 (39.17) | 140 (87.50) |
| Histologic grade | ||
| G1 | 42 (11.67) | 8 (5.00) |
| G2 | 205 (56.94) | 112 (70.00) |
| G3 | 113 (31.39) | 40 (25.00) |
| Cervical stromal invasion | ||
| <1/3 | 139 (38.61) | NA |
| 1/3−2/3 | 127 (35.28) | NA |
| >2/3 | 94 (26.11) | NA |
| LVSI | ||
| negative | 60 (16.67) | NA |
| positive | 300 (83.33) | NA |
| LN status (pathology) | ||
| Non-metastasis | 304 (84.44) | NA |
| Metastasis | 56 (15.56) | NA |
| LNSCT | ||
| No LN | NA | 80 (50.00) |
| LN diameter ≤1 cm | NA | 29 (18.13) |
| Single LN >1 cm | NA | 22 (13.75) |
| Multi LNs >1 cm | NA | 29 (18.13) |
| Recurrence | 42 (11.67) | 49 (30.63) |
| Survival | 320 (88.89) | 112 (70.00) |